287 studies found for:    "Breast Neoplasms, Male"
Show Display Options
RSS Create an RSS feed from your search for:
"Breast Neoplasms, Male"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting An Observational Registry-Based Study of a Potential Link Between Finasteride (MK-0906) and Male Breast Cancer in 4 Nordic Countries (MK-0906-162/2003.021)
Condition: Male Breast Cancer
Intervention: Drug: Finasteride
2 Recruiting A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
3 Completed Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
Condition: Breast Cancer
Intervention:
4 Completed
Has Results
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasms, Male;   Carcinoma, Ductal
Intervention: Drug: pemetrexed
5 Withdrawn Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Male Breast Cancer;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: external beam radiation therapy;   Other: questionnaire administration;   Procedure: therapeutic conventional surgery
6 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, And Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
8 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pineal Gland Astrocytoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Anaplastic Thyroid Cancer;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Cancer;   Extra-adrenal Paraganglioma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Gastrinoma;   Glucagonoma;   Hepatic Complications;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Insular Thyroid Cancer;   Insulinoma;   Intraocular Lymphoma;   Male Breast Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Pancreatic Polypeptide Tumor;   Peripheral T-cell Lymphoma;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Tumor;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Islet Cell Carcinoma;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Pheochromocytoma;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Thyroid Cancer;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Gastrointestinal Carcinoid Tumor;   Regional Pheochromocytoma;   Small Intestine Lymphoma;   Somatostatinoma;   Splenic Marginal Zone Lymphoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adult Soft Tissue Sarcoma;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Bladder Cancer;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Follicular Thyroid Cancer;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Melanoma;   Stage IIIC Rectal Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Melanoma;   Stage IV Neuroendocrine Carcinoma of the Skin;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Colon Cancer;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Papillary Thyroid Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Colon Cancer;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Papillary Thyroid Cancer;   Stage IVB Rectal Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Papillary Thyroid Cancer;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: romidepsin;   Other: pharmacological study
9 Recruiting Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Hormone-resistant Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: exemestane;   Drug: entinostat;   Drug: goserelin acetate;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
10 Terminated Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Male Breast Cancer;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Tumors Metastatic to Brain
Interventions: Drug: cediranib maleate;   Radiation: whole-brain radiation therapy
11 Completed Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: bevacizumab;   Drug: vinorelbine tartrate;   Other: laboratory biomarker analysis
12 Completed Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: trastuzumab
13 Completed Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Conditions: Inflammatory Breast Cancer;   Male Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: tipifarnib;   Drug: capecitabine;   Drug: docetaxel;   Other: laboratory biomarker analysis;   Other: pharmacological study
14 Active, not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
15 Terminated Pazopanib Hydrochloride and Anastrozole Before Surgery in Treating Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: anastrozole;   Drug: pazopanib hydrochloride;   Procedure: therapeutic conventional surgery
16 Terminated RO4929097 And Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Extensive Stage Small Cell Lung Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Radiation: stereotactic radiosurgery;   Radiation: whole-brain radiation therapy
17 Recruiting Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
Interventions: Drug: lapatinib ditosylate;   Radiation: whole-brain radiation therapy
18 Recruiting FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
19 Active, not recruiting Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Conditions: HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: paclitaxel;   Biological: bavituximab;   Other: laboratory biomarker analysis;   Other: pharmacological study
20 Recruiting Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years